Drug Profile

SIM 0711

Alternative Names: SIM-0711

Latest Information Update: 23 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Simcere Pharmaceutical Group
Class Small molecules
Mechanism of Action IRAK4 protein degraders

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Autoimmune disorders

Most Recent Events

24 Oct 2025 Simcere Pharmaceutical Group plans to file an IND application in China for Autoimmune disorders in third quarter of 2025
24 Oct 2025 Pharmacokinetics data from preclinical trial in Autoimmune disorders presented at ACR Convergence 2025 (ACR/ARP-2025)
11 Jul 2025 Preclinical trials in Autoimmune disorders in China (PO) (Simcere Pharmaceutical Group pipeline, October 2025)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com